Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

por Weng, Xiuhua, Luo, Shaohong, Lin, Shen, Zhong, Lixian, Li, Meiyue, Xin, Rao, Huang, Pinfang, Xu, Xiongwei
Publicado 2020

Detection of femtomolar level osteosarcoma-related gene via a chronocoulometric DNA biosensor based on nanostructure gold electrode

por Zhong, Guangxian, Liu, Ailin, Xu, Xiongwei, Sun, Zhouliang, Chen, Jinyuan, Wang, Kun, Liu, Qicai, Lin, Xinhua, Lin, Jianhua
Publicado 2012

Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion

por Li, Meiyue, Lin, Shen, Wilson, Leslie, Huang, Pinfang, Wang, Hang, Lai, Shubin, Dong, Liangliang, Xu, Xiongwei, Weng, Xiuhua
Publicado 2021

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab

por Lin, Shen, Li, Yiyuan, Gu, Dian, Luo, Shaohong, Huang, Xiaoting, Dong, Liangliang, Xu, Xiongwei, Lin, Peili, Weng, Xiuhua
Publicado 2022

Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis

por Huang, Xiaojia, Huang, Xiaoting, Lin, Shen, Luo, Shaohong, Dong, Liangliang, Lin, Dong, Huang, Yaping, Xie, Chen, Nian, Dongni, Xu, Xiongwei, Weng, Xiuhua
Publicado 2023

Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey

por Lin, Shen, Lin, Dong, Li, Yiyuan, Zhong, Lixian, Zhou, Wei, Wu, Yajing, Xie, Chen, Luo, Shaohong, Huang, Xiaoting, Xu, Xiongwei, Weng, Xiuhua
Publicado 2023

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks

por Lin, Shen, Huang, Yaping, Dong, Liangliang, Li, Meiyue, Wang, Yahong, Gu, Dian, Wu, Wei, Nian, Dongni, Luo, Shaohong, Huang, Xiaoting, Xu, Xiongwei, Weng, Xiuhua
Publicado 2023